Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Evommune (EVMN) Other Non-Current Assets (2024 - 2025)

Evommune (EVMN) has disclosed Other Non-Current Assets for 2 consecutive years, with $1.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Other Non-Current Assets rose 580.29% to $1.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.4 million, a 580.29% increase, with the full-year FY2025 number at $1.4 million, up 580.29% from a year prior.
  • Other Non-Current Assets was $1.4 million for Q4 2025 at Evommune, up from $61000.0 in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $1.4 million in Q4 2025 to a low of $61000.0 in Q3 2025.